The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
HOME > BUSINESS
BUSINESS
- EA Pharma Licenses Secondary Hyperparathyroidism Med AJT240 to JW Pharma
November 2, 2017
- Mitsubishi Tanabe’s HIF-PH Inhibitor Enters Japan PIII
November 2, 2017
- Eisai CEO Sees 4 Global Brands as Drivers through FY2020
November 2, 2017
- Eisai’s Half-Year Sales Grow on Global Brands, Profits Slide after EA Pharma One-Off Gain
November 2, 2017
- Mitsubishi Tanabe’s Half-Year Sales Up 4.5%, but Profits Dip on Radicava Promotion Costs
November 2, 2017
- Takeda Logs 3.6% Sales Rise, Double-Digit Profit Jump on Entyvio, Takecab
November 2, 2017
- Astellas Delivers Positive Data in 1st HIF-PH Inhibitor Study in Japan
November 1, 2017
- Aspen Takes Over Arixtra from GSK, Transfer Pact Completed in Japan
November 1, 2017
- Bristol-Myers France’s Barland to Become Japan President
November 1, 2017
- Kyowa Kirin Kicks Off Japan PIII for Regpara Follow-Up Evocalcet
November 1, 2017
- Daiichi Sankyo Shooting for Top Share for Lixiana by Tokyo Olympics: President
November 1, 2017
- Daiichi Sankyo Ekes Out 2.5% Sales Rise despite Olmetec LOE, Operating Profit Sags 33.5%
November 1, 2017
- Micardis Generic Penetration “Faster than Expected”: Astellas President
November 1, 2017
- Towa to Discontinue Sales of 34 Products due to Bulk Drug Supply Problems, Weak Demand
November 1, 2017
- Sumitomo Dainippon In-Licenses Diabetes Med from France’s Poxel
November 1, 2017
- Astellas’ Half-Year Operating Profit Down 38.8% on LLP Divestiture, Micardis Gx Erosion
November 1, 2017
- Global Sales of Shionogi’s Novel Influenza Drug Could Reach US$1 Billion: President
November 1, 2017
- Parkinson’s Disease Therapy Rasagiline Improves Average Daily Off-Time in Japan PII/PIII Study: Takeda
November 1, 2017
- Daiichi Sankyo Pairs Up with German Startup to Develop ADC for Solid Cancer
November 1, 2017
- Boehringer, Astellas to Extend Sales Pact for Micardis Family of Products to March 2020
November 1, 2017
ページ
The pharmaceutical industry is ever-changing. Recruiters must evolve accordingly and prepare well in advance for future talent needs.This means predicting the changes and trends that will impact the market, industry, and your organization, and how this will affect talent requirements.…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…